Brokerages Set Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) PT at $60.40

Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) have received a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $60.40.

A number of equities analysts have recently weighed in on IMCR shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunocore in a research report on Thursday, January 22nd. Zacks Research raised Immunocore from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, January 7th. Wells Fargo & Company began coverage on Immunocore in a research report on Friday, October 31st. They set an “overweight” rating and a $60.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a research report on Wednesday, February 4th. Finally, Wall Street Zen downgraded shares of Immunocore from a “buy” rating to a “hold” rating in a report on Saturday, January 31st.

Hedge Funds Weigh In On Immunocore

A number of large investors have recently added to or reduced their stakes in the company. Leonteq Securities AG bought a new stake in shares of Immunocore in the fourth quarter valued at about $30,000. GAMMA Investing LLC raised its holdings in shares of Immunocore by 51.6% in the third quarter. GAMMA Investing LLC now owns 914 shares of the company’s stock valued at $33,000 after purchasing an additional 311 shares during the last quarter. Harbour Investments Inc. lifted its position in shares of Immunocore by 60.2% in the fourth quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock worth $36,000 after purchasing an additional 388 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its position in shares of Immunocore by 4,696.3% in the second quarter. Caitong International Asset Management Co. Ltd now owns 1,295 shares of the company’s stock worth $41,000 after purchasing an additional 1,268 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC acquired a new position in Immunocore during the second quarter worth $42,000. Institutional investors own 84.50% of the company’s stock.

Immunocore Stock Up 0.3%

NASDAQ:IMCR opened at $32.93 on Monday. Immunocore has a 52-week low of $23.15 and a 52-week high of $40.71. The stock’s fifty day moving average price is $34.52 and its two-hundred day moving average price is $34.35. The company has a debt-to-equity ratio of 0.99, a quick ratio of 5.97 and a current ratio of 6.00. The company has a market cap of $1.66 billion, a price-to-earnings ratio of -57.77 and a beta of 0.78.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.